



AGENDA B

BREAKOUT SESSION: MCM RESEARCH AND DEVELOPMENT

BIOLOGICAL THREATS Balcony Room

The Fairfax at Embassy Row Hotel
2100 Massachusetts Avenue, NW
Washington, DC 20008

DAY ONE (November 4, 2009)

14:00 – 15:30

Moderator: Professor Daniel Gillet, Ph.D.

Deputy Chief and Coordinator, French RNBC Program
Department of Molecular Engineering of Proteins (SIMOPRO)
Biology and Technology Institute of Saclay (IBiTec-S)
French Atomic Energy Commission, France

14:00 – 14:20

BARDA/DOD Integrated BioDefense Medical Countermeasures Portfolio

Carol D. Linden, Ph.D.

Principal Deputy Director
Biomedical Advanced Research and Development Authority (BARDA)
Office of the Assistant Secretary for Preparedness and Response
Department of Health & Human Services, United States

14:20 – 14:40

U.K. BioDefense Medical Countermeasures Portfolio

Professor Nigel Lightfoot, CBE

Chief Advisor
Health Protection Agency, United Kingdom

14:40 – 15:00

Therapeutic Research Within the French RNBC Program and Broad-Spectrum Toxin Inhibitors Protecting Mice Against Ricin

Professor Daniel Gillet, Ph.D.

Deputy Chief and Coordinator, French RNBC Program
Department of Molecular Engineering of Proteins (SIMOPRO)
Biology and Technology Institute of Saclay (IBiTec-S)
French Atomic Energy Commission, France

15:00 – 15:20

Botulism Antitoxin (BAT), Anthrax Immune Globulin (AIG), and Ricin—Current Status

John Langstaff, Ph.D.

President and Chief Executive Officer
Cangene Corporation, Canada

15:20 – 15:30

Questions and Answers



15:30 – 15:50

BREAK

15:50 – 16:10

Treatment of Clostridium Botulinum Toxin Intoxications

Professor Walter Biederbick, Ph.D.

Director
Center for Biological Safety
Robert Koch-Institute
Ministry of Health, Germany

16:10 – 16:30

Botulism Diagnostics Challenges and Requirements

Susan Maslanka, Ph.D.

Team Lead
National Botulism Laboratory Preparedness Team
Centers for Disease Control and Prevention
Department of Health & Human Services, United States

16:30 – 16:50

NIAID MCM Research and Development at the Health Protection Agency

Miles Carroll, Ph.D.

Deputy Director, Research
Centre for Emergency Preparedness and Response
Department of Health, United Kingdom

16:50 – 17:10

Program Overview: Anthrax Vaccines and Therapeutics

Sukjoon Park, Ph.D.

Senior Director, Product Development
Emergent BioSolutions Inc., United States

17:10 – 17:30

Developing a New Generation of Anthrax Vaccines and Therapeutics

Matthew Duchars, Ph.D.

Chief Scientific Officer
PharmAthene, Inc., United States

Questions and Answers Will Follow Each Talk

17:30 – 18:00

GHSI GOVERNMENT MEMBERS CLOSED SESSION

Whitehall Room

18:00 – 20:00

POSTER SESSION AND RECEPTION

Ballroom



DAY TWO (November 5, 2009)

14:00 – 15:30

Moderator: Professor Daniel Gillet, Ph.D.
Deputy Chief and Coordinator, French RNBC Program
Department of Molecular Engineering of Proteins (SIMOPRO)
Biology and Technology Institute of Saclay (IBiTec-S)
French Atomic Energy Commission, France

14:00 – 14:20

Research and Developments in Smallpox Vaccine LC16m8

Tomoya Saito, M.D., Ph.D.
Instructor
School of Medicine
Keio University, Japan

14:20 – 14:40

The Development of a Broad-Spectrum Antiviral Agent, CMX001, for the Prophylaxis and Treatment of Smallpox

George Painter, Ph.D.
President and Chief Executive Officer
Chimerix, Inc., United States

14:40 – 15:00

DEF201 Broad-Spectrum Antiviral Development via Trilateral Cooperation

Jeffrey Turner, Ph.D.
President and Chief Executive Officer
Defyrus Inc., Canada

15:00 – 15:20

The French Anthrax Vaccine Program

Colonel Françoise Lévêque, Ph.D.
Head
Human Sciences and Protection Branch
Department of Defense, France

15:20 – 15:30

Questions and Answers

15:30 – 15:50

BREAK

15:50 – 16:50

BREAKOUT ROUNDTABLE

Biological Threats

Balcony Room

Moderator: Professor Nigel Lightfoot, CBE
Chief Advisor
Health Protection Agency, United Kingdom



16:50 – 17:00

BREAK

17:00 – 17:45

**PLENARY ROUNDTABLE:
GUIDELINES TO INTEGRATING POLICY AND RESEARCH
AND DEVELOPMENT FOR MCM**

Ballroom

Moderator: Monique K. Mansoura, Ph.D.

Director for Medical Countermeasure Policy, Planning, and Requirements
Biomedical Advanced Research & Development Authority (BARDA)
Office of the Assistant Secretary for Preparedness and Response
Department of Health & Human Services, United States

17:45 – 17:55

CLOSING REMARKS

Ballroom

Mary Mazanec, M.D., J.D.

Deputy Assistant Secretary

Director, Office of Medicine, Science, and Public Health
Office of the Assistant Secretary for Preparedness and Response
Department of Health & Human Services, United States

17:55 – 18:00

BREAK

18:00 – 18:45

GHSI GOVERNMENT MEMBERS CLOSED ROUNDTABLE

Whitehall Room